These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
232 related items for PubMed ID: 15723220
21. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. de Wit R, Herrstedt J, Rapoport B, Carides AD, Carides G, Elmer M, Schmidt C, Evans JK, Horgan KJ. J Clin Oncol; 2003 Nov 15; 21(22):4105-11. PubMed ID: 14559891 [Abstract] [Full Text] [Related]
22. Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects. Hsyu PH, Pignataro DS, Matschke K. Eur J Clin Pharmacol; 2017 Jan 15; 73(1):49-56. PubMed ID: 27718000 [Abstract] [Full Text] [Related]
23. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JH. Cancer Chemother Pharmacol; 2005 Jan 15; 55(1):72-8. PubMed ID: 15316750 [Abstract] [Full Text] [Related]
25. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects. Lasseter KC, Gambale J, Jin B, Bergman A, Constanzer M, Dru J, Han TH, Majumdar A, Evans JK, Murphy MG. J Clin Pharmacol; 2007 Jul 15; 47(7):834-40. PubMed ID: 17525168 [Abstract] [Full Text] [Related]
26. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. ten Tije AJ, Verweij J, Carducci MA, Graveland W, Rogers T, Pronk T, Verbruggen MP, Dawkins F, Baker SD. J Clin Oncol; 2005 Feb 20; 23(6):1070-7. PubMed ID: 15718305 [Abstract] [Full Text] [Related]
29. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Navari RM. Expert Rev Anticancer Ther; 2004 Oct 20; 4(5):715-24. PubMed ID: 15485308 [Abstract] [Full Text] [Related]
30. Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. Dandamudi UB, Adams LM, Johnson B, Bauman J, Morris S, Murray S, Webb RT, Gartner E, Hohl R, Lewis LD. Cancer Chemother Pharmacol; 2011 Apr 20; 67(4):783-90. PubMed ID: 20556613 [Abstract] [Full Text] [Related]
35. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson AS, Eckhardt SG. Cancer Chemother Pharmacol; 2003 Aug 20; 52(2):159-66. PubMed ID: 12759775 [Abstract] [Full Text] [Related]
38. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit Rd, Carides AD, Taylor A, Evans JK, Horgan KJ. Eur J Cancer; 2005 Jun 20; 41(9):1278-85. PubMed ID: 15939263 [Abstract] [Full Text] [Related]
39. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study. Freyer G, Hennebert P, Awada A, Gil T, Kerger J, Selleslags J, Brassinne C, Piccart M, de Valeriola D. Clin Cancer Res; 2002 Jan 20; 8(1):95-102. PubMed ID: 11801544 [Abstract] [Full Text] [Related]